Canaccord lowered the firm’s price target on 10x Genomics to $20 from $32 and keeps a Buy rating on the shares. The firm said their target decrease is driven by significantly reduced near- and long-term revenue estimates, although they think current levels offer a solid entry point for longer-term investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target lowered to $20 from $32 at Canaccord
- Closing Bell Movers: 10x Genomics falls 27% on’cautious’ customer spending
- 10x Genomics sees Q3 revenue $151.7M, consensus $162.24M
- 10x Genomics announces plan to deliver single cell analysis
- 10x Genomics initiated with an Outperform at Leerink
Questions or Comments about the article? Write to editor@tipranks.com